U.S. Futures Drop on China Stopping Some Imports: Markets Wrap

U.S. Futures Drop on China Stopping Some Imports: Markets Wrap

(Bloomberg) -- U.S. stock futures turned lower while European shares held onto modest gains after Chinese officials told agriculture companies to pause imports of some farm goods. Treasuries erased their earlier declines.State-owned traders Cofco and Sinograin were ordered to suspend purchases, according to a person familiar with the matter. The move raises the risk of heightening tensions between to the two countries and is the latest sign that the phase-one trade deal is in jeopardy.European equities climbed as investors focused on signs of economic recovery from the pandemic, with travel companies and banks leading gains in the Stoxx 600 Index. The dollar slid to its lowest since March.Asia’s session saw more risk-on sentiment. U.S. President Donald Trump on Friday stopped short of specifying tough sanctions over China’s new national security law for Hong Kong.Here are some key events coming up:Australia’s central bank is expected to keep its main policy programs unchanged...

China Halts Some U.S. Farm Imports, Including Soy Beans

Jun.01 -- Chinese government officials told major state-run agricultural companies to pause purchases of some American farm goods including soybeans as Beijing evaluates the ongoing escalation of tensions with the U.S. over Hong Kong, according to people familiar with the situation. Leslie Vinjamuri, head of U.S. and Americas Programme at Chatham House, reacts to the news on "Bloomberg Surveillance."...

Nordstrom’s Shares Drop 12% on Difficult Quarter

Nordstrom (JWN) reported its quarterly earnings on Friday, and the results were grim. Net sales dropped 40%, worse than the 33% decline expected by analysts.The company recorded an operating loss of $521 million for the quarter for a loss per share of $2.23. This represented a decrease from net earnings of $37 million during the same period in fiscal 2019, and fell starkly short of Street expectations of a $0.95 loss per share for the quarter. Its shares closed on Friday at $16.13, down more than 12% for the day.Nordstrom shuttered all of its stores on March 17. Some reopened in early May, while those in its key markets—California, New York and Washington—remain closed. Disappointingly, Nordstrom reported online-sales growth of only 5% in the quarter. As a result, Nordstrom reported that its SG&A expenses ballooned to 55% of net sales, compared with 34% of net sales for the same period in...

Trump Invokes Law-And-Order Image

Jun.01 -- Matthew Goodwin, professor of political and international relations at University of Kent, discusses President Donald Trump pivot to a law and order image amid the violent protests that are sweeping the country, how this could play out in the upcoming election in November and how coronavirus has impacted U.K. politics. Goodwin speaks on “Bloomberg Markets: European Open.”...

The Glamorous Life of a Freight Dispatcher in 2020!

Freight dispatchers don’t have it easy. What else is new? Actually there are several items which have been added to the freight dispatcher plate. In fact lately it seems they’ve had to pull out a second plate. The freight market has been punishing truck drivers and freight dispatchers have had to work extra hard to […]

Adaptimmune Spikes 127% Post-ASCO; Analyst Triples Price Target

Shares in UK-based biopharma Adaptimmune (ADAP) spiked 127% in Friday’s trading, after the company reported positive durability and efficacy data in synovial sarcoma at the American Society for Clinical Oncology (ASCO) Annual Meeting.The data demonstrated durability and responses in synovial sarcoma, supporting SPEARHEAD-1 as a potential registrational trial, ADAP announced. Dr David Hong spoke of a 50% response rate with inclusion of unconfirmed PR assessed after data cut-off. The ASCO presentation also described a new response in a patient with lung cancer, and a response in a patient with head and neck cancer.At the same time, Adaptimmune also announced new responses in the SURPASS trial, confirming the potential for SPEAR T‑cell therapies targeting MAGE-A4 to treat a broad range of cancers in addition to sarcoma. In the SURPASS trial, three patients have responded out of the first four treated with ADP-A2M4CD8, ADAP said.These data further support the rationale for two new Phase...